AstraZeneca earnings per share forecasts raised by Barclays
Barclays raised AstraZeneca's earnings per share forecasts after the biotech company penned a new deal on Tuesday
Company
AstraZeneca PLC
LON:AZN
AstraZeneca is one of the world's leading pharmaceutical companies, with a broad range of medicines designed to fight disease. AstraZeneca has over 67,000 empolyees and operates in over 100 countries with growing presence in important emerging markets.
1084 stories · page 14 of 55
AstraZeneca premium justified by long-term potential says broker
Pipeline prospects give a 13,000p/share target says Shore Capital
Brexit driving UK manufacturers to turn away from foreign suppliers
40% of UK manufacturers have looked to domesticate supply lines, while many EU firms are complacent about trading with British companies, Make UK says
AstraZeneca to acquire CinCor for US$1.8bn
CinCor's key treatment tackles the effects of diseases such as hypertension, diabetes and vascular defects
AstraZeneca posts mixed results from lung cancer trial
Imfinzi missed its primary endpoint but achieved its secondary result
FIVE at FIVE: UK inflation eases; BT price changes probed by Ofcom; AstraZeneca assessed; Sam Bankman-Fried denied bail
Here’s Proactive’s round-up of the top financial stories of the day, with helpful links taking you directly to the news